Precision Biosciences saw the highest growth of 3.99% in patent filings in May and 0.49% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.16% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Precision Biosciences‘s patent filings and grants. Buy the databook here.
Precision Biosciences has been focused on protecting inventions in United States(US) with five publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 38% filings and 67% grants. The United States(US), Australia(AU), Israel(IL), and European Patent Office(EPO) patent Office are among the top ten patent offices where Precision Biosciences is filings its patents. Among the top granted patent authorities, Precision Biosciences has 67% of its grants in United States(US) and 33% in Israel(IL).
Patents related to rare diseases and genomics lead Precision Biosciences's portfolio
Precision Biosciences has the highest number of patents in rare diseases followed by, genomics and genetically modified organism (GMO). For rare diseases, nearly 38% of patents were filed and 50% of patents were granted in Q2 2024.
Duchenne muscular dystrophy related patents lead Precision Biosciences portfolio followed by liver cancer, and ataxia
Precision Biosciences has highest number of patents in duchenne muscular dystrophy followed by liver cancer, ataxia, epileptic encephalopathy, and neuropathy. For duchenne muscular dystrophy, nearly 15% of patents were filed and 33% of patents were granted in Q2 2024.
For comprehensive analysis of Precision Biosciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.